Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Total Non-current Liabilities
All obligations due after more than one year.
Turn Therapeutics Inc.NASDAQ: TTRX
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities of $7.4M in Q1 FY2026
Q1 FY2026 total non-current liabilities was $7.4M.
Context
- Total non-current liabilities amounted to 39.7% of total assets at the end of Q1 FY2026.
- Total non-current liabilities increased in 1 of the last 2 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.47M USD
- Year-over-year change
- -3.0%
- 2-year CAGR
- +1.2%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.47M | -3.0% |
| FY2024 | 2024-12-31 | 1.52M | +5.6% |
| FY2023 | 2023-12-31 | 1.44M | — |
Total Non-current Liabilities vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's Mar 2026 total non-current liabilities of $7.4M is the 4th highest of the 9 companies compared; the peer median is $312K.
- Total non-current liabilities amounts to 39.7% of total assets for TTRX, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $165.2M | -47.4% | -13.5% | 88.6% | |
IRDOpus Genetics, Inc. | Mar 2026 | $103.28M | +448.1% | — | 154.6% |
| Mar 2026 | $20.41M | -11.5% | -9.4% | 7.5% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $7.4M | — | — | 39.7% |
| Mar 2026 | $447.99K | — | +189.2% | 1.5% | |
| Mar 2026 | $176K | -37.1% | -56.6% | 0.5% | |
| Apr 2026 | $140K | -23.9% | -2.3% | 0.9% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TTRX) | $312K | -23.9% | -9.4% | 1.2% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.